stoxline Quote Chart Rank Option Currency Glossary
  
Apexigen, Inc. (APGN)
0.3851  0.03 (8.48%)    08-22 15:59
Open: 0.3601
High: 0.3963
Volume: 94,426
  
Pre. Close: 0.355
Low: 0.3551
Market Cap: 10(M)
Technical analysis
2023-10-20 4:21:55 PM
Short term     
Mid term     
Targets 6-month :  0.48 1-year :  0.52
Resists First :  0.41 Second :  0.44
Pivot price 0.38
Supports First :  0.35 Second :  0.29
MAs MA(5) :  0.38 MA(20) :  0.39
MA(100) :  0.44 MA(250) :  1.4
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  32.3 D(3) :  32.2
RSI RSI(14): 44.2
52-week High :  8.27 Low :  0.33
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ APGN ] has closed above bottom band by 45.6%. Bollinger Bands are 56.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 117 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.39 - 0.39 0.39 - 0.39
Low: 0.38 - 0.38 0.38 - 0.38
Close: 0.38 - 0.39 0.39 - 0.39
Company Description

Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.

Headline News

Tue, 30 Jan 2024
Meenu Chhabra Karson Joins Bedford Group Transearch Advisory Board - citybiz

Thu, 25 May 2023
Apexigen (APGN) to Be Acquired by Pyxis Oncology (PYXS) at $0.64 Per Share|SPACInsider - SPACInsider

Thu, 25 May 2023
Apexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up - Yahoo Finance

Wed, 24 May 2023
Small SPAC Biotech Apexigen To Be Acquired Pyxis Oncology For $16M - Yahoo Finance

Wed, 24 May 2023
Pyxis Oncology to Acquire Apexigen - GlobeNewswire

Mon, 20 Mar 2023
Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Australia

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 25 (M)
Held by Insiders 2.208e+007 (%)
Held by Institutions 8.8 (%)
Shares Short 105 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.775e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -89.5 %
Return on Equity (ttm) -1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 165.2
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -26 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -15.49
Stock Dividends
Dividend 0
Forward Dividend 64450
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android